Nature Communications (Feb 2016)
Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents
- Jane Merlevede,
- Nathalie Droin,
- Tingting Qin,
- Kristen Meldi,
- Kenichi Yoshida,
- Margot Morabito,
- Emilie Chautard,
- Didier Auboeuf,
- Pierre Fenaux,
- Thorsten Braun,
- Raphael Itzykson,
- Stéphane de Botton,
- Bruno Quesnel,
- Thérèse Commes,
- Eric Jourdan,
- William Vainchenker,
- Olivier Bernard,
- Noemie Pata-Merci,
- Stéphanie Solier,
- Velimir Gayevskiy,
- Marcel E. Dinger,
- Mark J. Cowley,
- Dorothée Selimoglu-Buet,
- Vincent Meyer,
- François Artiguenave,
- Jean-François Deleuze,
- Claude Preudhomme,
- Michael R. Stratton,
- Ludmil B. Alexandrov,
- Eric Padron,
- Seishi Ogawa,
- Serge Koscielny,
- Maria Figueroa,
- Eric Solary
Affiliations
- Jane Merlevede
- INSERM U1170, Gustave Roussy
- Nathalie Droin
- INSERM U1170, Gustave Roussy
- Tingting Qin
- Department of Pathology, University of Michigan Medical School
- Kristen Meldi
- Department of Pathology, University of Michigan Medical School
- Kenichi Yoshida
- Department of Pathology and Tumour Biology, Kyoto University
- Margot Morabito
- INSERM U1170, Gustave Roussy
- Emilie Chautard
- Université Lyon 1, UMR CNRS 5558, Université Claude Bernard
- Didier Auboeuf
- Centre Léon Bérard, INSERM U1052, CNRS UMR5286
- Pierre Fenaux
- Department of Hematology, Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis
- Thorsten Braun
- Department of Hematology, Assistance Publique–Hôpitaux de Paris
- Raphael Itzykson
- Department of Hematology, Assistance Publique–Hôpitaux de Paris, Hôpital Saint-Louis
- Stéphane de Botton
- INSERM U1170, Gustave Roussy
- Bruno Quesnel
- Cancer Research Institute de Lille, INSERM U837
- Thérèse Commes
- Institut de médecine régénératrice, Biothérapie et Institut de biologie computationnelle, INSERM U1040, Université de Montpellier
- Eric Jourdan
- Department of Hematology, Centre Hospitalier Universitaire de Nîmes, Université Montpellier-Nîmes
- William Vainchenker
- INSERM U1170, Gustave Roussy
- Olivier Bernard
- INSERM U1170, Gustave Roussy
- Noemie Pata-Merci
- INSERM US23, CNRS UMS3655, Gustave Roussy
- Stéphanie Solier
- INSERM U1170, Gustave Roussy
- Velimir Gayevskiy
- Laboratory of Genome Informatics, Kinghor Center for Clinical Genomics, Garvan Institute of Medical Research
- Marcel E. Dinger
- Laboratory of Genome Informatics, Kinghor Center for Clinical Genomics, Garvan Institute of Medical Research
- Mark J. Cowley
- Laboratory of Genome Informatics, Kinghor Center for Clinical Genomics, Garvan Institute of Medical Research
- Dorothée Selimoglu-Buet
- INSERM U1170, Gustave Roussy
- Vincent Meyer
- Centre National de Génotypage
- François Artiguenave
- Centre National de Génotypage
- Jean-François Deleuze
- Centre National de Génotypage
- Claude Preudhomme
- Cancer Research Institute de Lille, INSERM U837
- Michael R. Stratton
- Cancer Genome Project, Wellcome Trust Sanger Institute
- Ludmil B. Alexandrov
- Cancer Genome Project, Wellcome Trust Sanger Institute
- Eric Padron
- Department of Hematology, Malignant hematology, H. Lee Moffitt Cancer Center
- Seishi Ogawa
- Department of Pathology and Tumour Biology, Kyoto University
- Serge Koscielny
- Department of Biostatistics, Gustave Roussy Cancer Center
- Maria Figueroa
- Department of Pathology, University of Michigan Medical School
- Eric Solary
- INSERM U1170, Gustave Roussy
- DOI
- https://doi.org/10.1038/ncomms10767
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 13
Abstract
Chronic myelomonocytic leukaemia is treated with agents that modify DNA methylation but whether they have direct cytotoxic effects is unclear. Here, the authors show that cells from treated patients show marked methylation changes without altered somatic mutation burden, suggesting that cytotoxicity is not a major factor in therapeutic efficacy.
